About Careers MedBlog Contact us

Novartis Develops New Drug for Advanced Lung Cancer

by Julia Samuel on February 28, 2015 at 3:40 PM
Font : A-A+

Novartis Develops New Drug for Advanced Lung Cancer

Swiss drug manufacturers Novartis have developed a drug for advanced lung cancer. European health regulators have recommended approval of the drug, which is intended to treat patients with a specific genetic mutation.

A new class medicines Zykadia, or ceritinib known as ALK (Anaplastic lymphoma kinase) inhibitors was approved last year in the United States.


It is designed for use in non-small cell lung cancer patients who have previously been treated with another ALK inhibitor, Pfizer's Xalkori.

The drug is targeted for a specific mutation of the ALK protein found mainly in 2 - 7 percent of non-small cell lung cancer patients.

Source: Medindia

Recommended Reading

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Novartis Develops New Drug for Advanced Lung Cancer Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests